Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer

 
• By Mandy Jackson
Pulmonology vector illustration
Amgen continues to explore monotherapy, combinations and biomarkers for sotorasib in lung cancer • Source: Shutterstock

More from Clinical Trials

More from R&D